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Abstract  
Background: Atrial septal defect (ASD) is a common congenital heart disorder (CHD). While 
conventional open surgical treatment is the standard procedure in our country, percutaneous device 
closure with implantation of an atrial septal defect occluder is a promising alternative with very few 
peri and post procedural complications. 
Aim: The aim of the study was to present the rate of success and complications in percutaneous 
ASD closure with the implantation of an atrial septal defect occluder. 
Material and Methods: We treated 153 patients (ages 2-76; 65% female) with ASD secundum with 
percutaneous trans catheter closure using a septal occluder. Follow up was on a 3 month interval 
and assessment included clinical, electrophysiological and echocardiographic status.  
Results: The mean diameter of ASD obtained via balloon sizing was 16 ± 16 mm. Multiple ASDs 
were found in 20 (13%) patients and deficitary aortic and anterior rim (< 5 mm) was present in 16 
(10%) patients. Due to inadequate placement and/or sizing, the device was removed and replaced 
in seven patients (5%). During follow up, trivial shunt was present in 4 (2.6%) patients. The 
diameter of the right ventricle corrected for age was reduced by an average of 20% by the first 
month and in 130 (86%) of patients it had normalized by one year of follow up. During follow up, 16 
(10%) patients reported transient headaches and 3 (1.9%) patients had transient atrial fibrillation 
(AF). 
Conclusion: In conclusion, the implantation of a septal occluder was found to be a safe procedure 
that resulted in improved hemodynamic parameters that result from right ventricular volume 
overload with favorable short- and mid-term results. 
 
 
 
 
 
 
 
 
Introduction 
Congenital heart disease has a prevalence of 
8-12 cases per 1000 live births. ASD is a common 
congenital heart disorder comprising of10 % of all 
CHD [1-6]. In utero, heart tissue can be seen on 
the18
th
 or 19
th
 day of fetal life. The atrial septum starts 
to form in the fourth week and is completely formed by 
the end of the fifth week of pregnancy, with formation 
of the septum primum, ostium primum and septum 
secundum. 
There are four basic forms of ASD [1-9]. The 
ostium secundum defect (Figure 1), the most common 
and benign form originates in the region of the fossa 
ovalis and is believed to develop as a result of 
exaggerated fenestration or resorption of the septum 
primum, underdevelopment of the septum secundum 
or a combination of the two. The underdevelopment of 
the septum secundum is often associated with atrial 
septal aneurysm (ASA). This is probably due to the 
extra tissue in the region of the fossa ovalis and it 
could be associated with a mitral valve prolapse or 
atrial arrhythmias. 
The second type of ASD is an ostium primum 
defect thought to result from the inability of the 
endocardial tissue to close the ostium primum. This 
type of defect is almost always associated with a 
mitral valve cleft. 
The third type of ASD is the sinus venosus 
defect. It is located in the posterior part of the septum, 
close to the superior vena cava and it could be 
associated with partial abnormal drainage of the upper 
right pulmonary vein or the inferior vena cava. 
Milev et al. Percutaneous Interventional Treatment of Atrial Septal Defect Secundum in Macedonia 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Mar 15; 2(1):62-67.                                                                                                                                                                               63 
 
The fourth type of ASD is a coronary sinus 
septal defect. This is the most uncommon variation of 
ASD, also known as unroofed coronary sinus. Part of 
the roof of the coronary sinus is missing so there 
could be a shunt from the left atrium to the coronary 
sinus and then to right atrium. It is usually associated 
with anomaly of the superior vena cava. 
  
Figure 1:  ASD ostium secundum type. 
 
ASD is the second most common CHD and it 
is present in 0, 67-2 out of 1000 live births. Ostium 
secundum represents 90% of ASD cases.  In 15-30% 
of adults there is an open persistent foramen ovale 
(PFO) with normal valve function and without 
spontaneous left to right shunt.  Developed countries 
have a very low (<1%) mortality rate.  In majority of 
cases the cause is a spontaneous malformation of the 
interatrial septum although genetic factors play a role 
in some syndromes ( Holt- Oram Sy., Klinefelter Sy., 
Down Sy.) [1, 6]. 
Clinical effects from isolated ASD usually 
correlate with the size of the left to right shunt which 
depends on the size of the defect and relative 
compliance of the left and right ventricle and indirectly 
depends on the resistance of pulmonary and systemic 
circulation [10-14].  About 15% of ostium secundum 
ASD close spontaneously by the age of four and in 
some cases it retrogrades to a non-significant 
hemodynamic shunt that does not require 
intervention. The clinical manifestation usually 
belongs to one of three groups. First, babies with 
moderate or severe isolated ASD present with 
tachypnea, respiratory infections and failure to thrive. 
In these patients the pulmonary arterial pressure 
measured during catheterization or with Doppler 
echocardiography approaches or is equal to the 
systemic arterial pressure. The second category of 
patients is those in whom the ASD remains 
undiagnosed until adulthood and usually presents with 
pulmonary hypertension or arrhythmia (atrial 
fibrillation or atrial tachycardia). In elderly patients, the 
first manifestation might be chronic heart failure. 
Embolic cerebral stroke could be the first presentation 
in the third group of patients with ASD. 
Diagnosis is usually made after detection of a 
murmur in babies and accidental or symptom related 
finding in adults where echocardiographic examination 
reveals a septal defect with or without right heart 
volume overload [15-18]. Transesophageal echo-
cardiography (TEE) may be performed for a more 
precise evaluation and sizing of the defect as well as 
magnetic resonance and/or cardiac catheterization in 
some cases. 
Medical treatment of a significant ASD with 
right ventricle volume overload should be according to 
heart failure guidelines. Arrhythmias (atrial fibrillation 
and atrio-ventricular blocks) associated with the defect 
are uncommon during childhood but their incidence 
increases with age (1-4%).   
Surgical closure is the treatment of choice for 
most types of ASD except for ostium secundum. 
Dimensions of up to 6 mm and no progression of 
diameter ordinarily do not necessitate intervention and 
the likelihood of spontaneous closure is approximately 
50%.  Surgical treatment involves direct suture or 
patch plastic with autologous pericardium or synthetic 
patches made of polyester polymer (Dacron) or 
polytetrafluoroethylene. Surgery is indicated in those 
cases with clinically significant left-to-right shunt 
(Qp/Qs≥ 1.5:1) and is ideally performed between the 
ages of 2 and 4 years. Mortality rates in experienced 
centers are less than 1%. 
Interventional trans-catheter treatment of 
patients in selected pediatric and adult populations is 
rising and is now the established practice in most 
cardiac centers in developed countries. Minimal 
invasiveness, avoidance of sternotomy and cardio-
pulmonary bypass are some of the advantages over 
open surgical treatment. Potential disadvantages are 
residual shunt, embolization of the device and 
insufficient rims for proper implantation. 
The aim of our study was to present the rate 
of success and complications in percutaneous ASD 
closure with the implantation of an atrial septal defect 
occluder done at our institution during a ten year 
period. 
 
Materials and Methods 
Between December 2003 and October 2013, 
153 patients (ages 2-76; 65% female) with ASD 
secundum were treated with percutaneous trans 
catheter closure using a septal occluder. The body 
surface area (BSA) of patients was 1.2 ± 0.6  kg/m
2
  
and 99 (65%) patients were younger than 14 years of 
age.  
Inclusion criteria for intervention were 
presence of ostium secundum ASD with left-to right 
shunt;right ventricular volume overload with paradoxal 
septal motion; diameter of ASD less than 34 mm and 
length of interatrial septum 14 mm longer than the 
size of the ASD; sufficient rims with 5 mm minimal 
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distance from the surrounding heart structures.  
The septal occluder device was made of a 
special nickel-titanium net. It is expandable and it is 
compressed in to an introducer. When the disc was 
released from the introducer it expanded to take its 
original shape. The central waist closed the defect 
and prevented shunts. The waist thickness was 4 mm 
and the length was between 6 and 40 mm. The left 
disc, the one that occluded the defect was 14 mm 
larger than the body of the device. The right disc was 
self-centering and had a screw that was released after 
implantation. 
In eight children (5.2%) the procedure was 
performed under general anesthesia with TEE guiding 
the implantation. In 40 (26%) adults TEE was 
performed before unscrewing the device. After 
percutaneous puncture of the left or right femoral vein, 
a 5 or 6F introducer was placed. Using a multipurpose 
catheter, the ASD was crossed and positioned in the 
left upper pulmonary vein. Stiff guide wire was passed 
and through it a balloon catheter of a size 
corresponding to the size of the defect was placed in 
the middle of the opening. Using contrast, the edges 
of the defect were visualed through an impression 
from the balloon after the proper device size was 
chosen. The balloon catheter was pulled out and the 
implantation system consisting of the long guide-wire, 
long introducer, implantation cable and the occlude 
device was prepared.  The guide-wire and the long 
introducer were positioned in the left atrium and then 
the wire and guide were carefully pulled out making 
sure not to create a vacuum that could lead to an air 
embolism. When the long introducer was released, an 
implantation cable with the device attached to it was 
passed through it. First, we opened the left disc in the 
left atrium and then the system was pulled back 
carefully and with echocardiographic control the right 
disc was released.  With the implantation cable still 
attached, the position of the occluder was analyzed 
using the, Minesota maneuver in order to ensure the 
stability of the device after it is released (Figure 2).  
 
Figure 2: Implanted atrial septal defect occluder. 
Medical management of all patients included 
one dose of pre-operative antibiotics and aspirin with 
the addition of clopidogrel daily for 6 months post 
intervention in higher risk patients. Post-interventional 
follow up was performed at a 3 month interval for a 
period of one year. It included clinical evaluation, 
echocardiographic examination and 24 h Holter 
monitoring in patients with evidence of or clinical 
suspicion of arrhythmias.  
 
Results 
All of the adults in our 153 patient cohorts 
went through a detailed TEE examination 
preinterventionaly and in patients over 40 years of age 
with risk factors for coronary artery disease 
coronarography was performed.   
The mean diameter of the defect as 
measured by TEE or TTE (transthoracic 
echocardiography) was 4 mm shorter than the 
angiographicaly-measured diameter.  In 8 (5.2%) 
patients more than one defect was found. Right 
ventricle pressures were normal in all patients. 
Fluoroscopy time varied between 9-35 minutes. The 
size of the implanted ocludders was 8-36 mm. In 7 
(4.5%) patients the initial device was replaced with a 
bigger one while the long introducer was still in the left 
atrium. 
Minor early complications (Table 1) occurred 
in 6 (3.9%) patients: 4 short episodes of supra 
ventricular tachycardia (TPSV) that was treated with 
Adenosin and 2 short episodes of ST segment 
elevation with spontaneous resolution. In 8 (5%) 
patients trivial left-to-right shunt remained and one 
patient had minor pericardial effusion. All but two 
patients were discharged from the hospital after 24 
hours.  
Table 1: Early complications in percutaneous ASD closure. 
Early complications                                                  Patients (9.8 %) 
Short episodes of supraventricular tachycardia                    4 (2.6) 
Short episodes of ST segment elevation                               2 (1.3%) 
Remained trivial left-to-right shunt                                         8 (5.2%) 
Minor pericardial effusion                                                       1 (0.7%) 
 
 
Follow up time postintereventionaly was 12 
months. On the last echocardiographic examination 
persistent small (less than 2 mm) left-to-right shunt 
was noted. Echocardiographic measurement of the 
right ventricle (RV) dimensions corrected for age 
showed a significant decrease (20% reduction in size 
from those before the intervention) by the first month. 
Paradoxal septal motion was present in 95% of 
patients before ASD closure and it persisted after one 
year follow-up in 2 (1.3%) patients (Figure 5). Two 
patients reported palpitations that needed 24 h EKG 
Holter monitoring that registered short episodes of 
atrial fibrillation. Nine (5.8%) patients reported 
transient headaches that significantly reduced in 
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intensity and frequency by the sixth month follow up.  
One patient reported transient sight changes that 
were further examined and did not show any 
significant cerebral ischemic involvement. 
 
Figure 3: Percentage of patients with increased right ventricular 
dimension and paradoxal septal movement before procedure and 
after one year follow-up. 
 
 
Discussion 
In our study we documented short and mid-
term results from trans-catheter closing of small, 
medium and large ASDs with intracardial prosthesis 
(Amplatzer or Cera atrial septal defect occluder) The 
procedure not only improved the hemodynamic but 
also the clinical status of all patients above 18 years 
of age and in younger ones prevented further right 
heart volume overload. The reduction in the size of 
the right ventricle could last 6-12 months and in some 
adult patients it could never be normalized. In patients 
with a persistent small shunt, despite the remaining 
defect there was substantial clinical improvement 
[18,19].  
There is no doubt that the presence of an 
ASD is a risk factor for development of atrial fibrillation 
(AF) that may occur despite early closure. Prevalence 
of AF exponentially increases with age. In a study 
done by Roos-Hesselink, patients average age 33 
years had a 3% prevalence of AF [20]. This is a 100-
times higher frequency than what is normally found in 
the general population of people between 45-49 years 
of age. 
In response to the above study, Swan and 
Gatzoulis proposed that early closure is the key to 
preventing late arrhythmias [21, 22]. Even though 
there are number of reasons for early closure of 
significant ASDs, there still is insufficient evidence that 
early closure plays a role in regressing arrhythmias. 
However, electrophysiological studies comparing 
patients with surgical ASD closure and those with 
percutaneous intervention showed significant 
reduction of incidence of late arrhythmias in the 
second group, suggesting that perhaps the absence 
of a surgical scar may reduce the predisposition to 
rhythm disturbances. 
Percutaneous closure of larger and 
complicated ASDs is in need of special attention and 
interventional expertise. Undeveloped posteroinferior 
and anterosuperior septal rim are factors that 
influence the choice of interventional technique [23, 
24]. During percutaneous ASD closure, the following 
complications have been described in the literature 
[25]: 
● Malpositioning and embolization of the device. 
The incidence is mostly dependent on operator 
expertise and adequate selection of patients. With an 
experienced interventional cardiologist, the incidence 
is less than 1%. In the study done by Chessa and 
Carminati, of the 417 patients analyzed, 10 (2.4%) of 
them needed surgical intervention because of device 
migration and embolization [26]. In our study there 
were no such complications. 
● The incidence of arrhythmias during the 
implantation process or after [27-29] is 1-4% and it 
involves supraventricular tachycardia (TPSV), atrial 
fibrillation and atrio-ventricular heart block from first, 
second or third degree. Usually the episodes were of 
short duration and did not require medical treatment. 
We report 4 (2.6%) patients with TPSV during the 
implantation process who were treated with adenosine 
and resolved a few minutes after application.  
● Thrombus formation can be a fatal complication 
and it is dependent on anti-thrombotic medication in 
the treated patients. One study of 1000 patients 
showed that the incidence of thrombus formation is 1, 
2% and usually forms between the fourth and the sixth 
week after the procedure. Risk factors are AF 
episodes, incomplete endotelialization of the device, 
non-compliance with therapy and hypercoagulability 
states and medication resistance [30-35]. In our 
series, all of the patients received Aspirin 5-10 mg/kg 
daily and 85% of adults received double 
antithrombotic therapy with aspirin 100 mg/day and 
clopidogrel 75 mg/day. 
● Heart perforation, with incidence of 0, 1-0, 4%. 
The greatest risk for this devastating complication is 
over-sizing of the device and deficitary rims. A 
retrospective study of 24 patients showed that all of 
the patients presented with chest pain, hemodynamic 
collapse and sudden death. Seventy five percent of 
patients were females and in 70% of them the 
complication presented after discharge [36, 37]. All of 
our patients had an echocardiographic examination 
before discharge and only one female adult was noted 
to have small pericardial effusion that was followed as 
an inpatient case. It resolved after 72 hours and the 
patient was discharged in good health. 
● Increased troponin levels can occur as a result of 
minor myocardial lesions. The risk increases with the 
age of the patient and the size of the occluder. We 
had one patient with transitory ST segment elevation 
but without increased levels in the cardiac markers. 
● Residual shunts persist in 20% of patients, 24 
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hours after intervention. Ninety percent of those are 
non-significant. We had four (2.6%) patients with 
residual shunt that was 2 mm or less [38]. 
● Transitory ischemic attack (TIA), cerebro-vascular 
insult (CVI) or sudden death happens rarely as a 
result of the procedure [39]. 
● The relatively high incidence of transient 
headaches (35% of adults according to Handke et all) 
after device implantation is a very interesting 
observation although the cause is unclear [39]. It is 
likely that these are a result of vasoactive substances 
released from platelets during the early period of 
endothelialization. Hemodynamic changes such as 
the increase in pressure in the left atrium as a result of 
distension caused by the implanted device can also 
be causing the release of vasoactive substrate [39-
43]. 
Potential risk of paradoxal embolization in 
patients with a residual atrial septal defect after 
transcatheter closure remains speculative. Prewitt et 
all reported TIA incidences in patients six months after 
closure with the Clamshell device and residual 
bidirectional shunt. After surgical closure it has been 
verified incomplete device endothelialization [43].  
The deal ASD closure device should have the 
following characteristics: simple implantation 
technique, possibility for re-implantation before 
detachment, stability during detachment, low 
complication rates for migration, thrombus formation, 
perforations and possibility for bio absorption. 
The study by Berger and Vogel compared 
open surgical to percutaneous interventional closure 
of ASD in a series of 90 patients. The results in terms 
of complete closure and complications are similar but 
the duration of hospitalization was shorter in the 
second group. Avoidance of a surgical scar and 
extracorporeal circulation and shorter hospitalization 
period favours the use of percutaneous intervention 
[44]. 
In conclusion, percutaneous implantation of a 
septal occluder in patients with atrial septal defect 
corrects and prevents hemodynamic changes that 
would normally occur due to right ventricular volume 
overload with low peri- and short and mid-term post 
procedural complication rates.  
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